Advanced therapies, in particular biologics and specialty medications, continue to drive demand in dermatology. On the one hand, these treatments provide very effective clinical benefits; on the other hand, payers scrutinize them very closely. Dermatology prior authorization requirements have thus grown more complex, with longer timelines for approval compared to most other specialties.
For clinics, this translates to delays, extra paperwork, and frustrated patients waiting for treatment. Practices can minimize delays in dermatology treatment approvals, even prevent denials, if the proper processes are implemented. The following are the key strategies that help stay ahead of payer rules and handle authorizations of high-cost therapies more effectively.
Why Dermatology Authorizations Are More Often Delayed
The main reason dermatology treatment approval delays are so common is high-cost drug oversight. Payers want to have proof that this therapy is medically necessary, cost-appropriate, and used only after conservative care. Common bottlenecks include:
- Lacking or outdated clinical notes
- Lack of previous treatment documentation
- Missing/wrong drug dosage information
- Payer-specific forms not submitted
- Missing lab results are required for safety
- Frequent changes to the rules for prior authorization of biologic medications
- Understanding where these delays occur helps practices build stronger workflows.
Strengthen Documentation to Support Medical Necessity
Dermatology prior auth denials often begin with incomplete documentation. Payers want a detailed picture of the patient’s history and condition. Clinical notes should include:
- Diagnosis with severity scoring
- Duration and course of the disease
- Previous treatment with topical, oral, or phototherapy
- Measured response or failure of previous therapies
- Impact on the patient’s quality of life
- Dosing of drugs, frequency, and duration are anticipated
- The more complete the documentation, the faster the approval.
- Only in the dimension of choice is there true freedom.
Use Payer-Specific Checklists
Each insurer handles high-cost dermatology drugs differently; some want step-therapy documentation, while others require certain scoring tools. Establish internal checklists regarding:
- Biologic medication prior authorization forms
- Other required laboratory tests (TB screening, liver function, etc.)
- Information required by the payer to facilitate therapy
- Payer drug formularies and medication tier structure
- Payer-specific prior authorization criteria for individual drugs
Timely Submission of Documentation
Since the approval of the biologics is a lengthy process, the early submission of the documentation will help facilitate the approval faster. To assist in developing good submission practices, it is important to:
- Begin the submission as soon as possible after the provider recommends therapy.
- Gather and keep all clinical notes and laboratory results prior to submitting for approval.
- Utilize electronic submission portals for the fastest submission.
- Check the status 48-72 hours after the initial submission.
- Escalate urgent cases with the appropriate supporting documentation.
- Taking these actions will minimize the chance of treatment gaps or delays in treatment.
Medical billing outsourcing can help when workloads are rising. When Dermatology clinics experience a high volume of biologics, authorization often fails to keep up. Outsourcing the process decreases delays and denials. A medical billing department that partners with a knowledgeable outsourced medical billing company like RCM Workshop can reap a more efficient process for tracking and updating submissions regarding high-cost treatments.
Dermatology practices that utilize an effective approach can streamline their dermatology prior authorization, reduce the number of denials they may receive, speed up the timeframe for patients receiving pre-approval for treatment, and ensure that all of their patients receive the timely and appropriate care they need.
